SRR650168
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- MYC_TARGETS_V1+0.460
- MYC_TARGETS_V2+0.410
- G2M_CHECKPOINT+0.360
- SPERMATOGENESIS+0.350
- PANCREAS_BETA_CELLS+0.320
- KRAS_SIGNALING_DN+0.240
- APICAL_SURFACE+0.170
- MTORC1_SIGNALING+0.130
- OXIDATIVE_PHOSPHORYLATION+0.130
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.450
- TGF_BETA_SIGNALING-0.430
- TNFA_SIGNALING_VIA_NFKB-0.430
- UV_RESPONSE_DN-0.410
- HYPOXIA-0.340
- APOPTOSIS-0.330
- P53_PATHWAY-0.330
- WNT_BETA_CATENIN_SIGNALING-0.300
- ANDROGEN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_RSRPX3S8 | medulloblastoma | — | 0.883 |
| 2 | BS_FKDQJJB5 | medulloblastoma | — | 0.855 |
| 3 | MNG541 | — | — | 0.851 |
| 4 | BS_R439VVPK | medulloblastoma | — | 0.848 |
| 5 | TCGA-A2-A04U-01A-11R-A115-07 | — | E | 0.847 |
| 6 | C3L-01285 | — | cohortSQ2 | 0.836 |
| 7 | BS_JZRM1S3T | medulloblastoma | — | 0.834 |
| 8 | BS_2Z1MKS84 | medulloblastoma | — | 0.830 |
| 9 | SRR8943040 | — | — | 0.830 |
| 10 | AUR-AFR5-TTM1-A-1-1-R-A743-41 | — | E | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |